Cue2Walk, Cost-effectiveness of Automated Freezing Detection and Provision of External Cues in Comparison to Usual Care in People With Parkinson's Disease - Trial NCT06416345
Access comprehensive clinical trial information for NCT06416345 through Pure Global AI's free database. This phase not specified trial is sponsored by Amsterdam UMC, location VUmc and is currently Not yet recruiting. The study focuses on Parkinson Disease. Target enrollment is 84 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Amsterdam UMC, location VUmc
Timeline & Enrollment
N/A
Sep 01, 2024
Sep 01, 2027
Primary Outcome
Self-reported quality of life,General health-related quality of life,Time in Freezing of Gait
Summary
The majority of people with Parkinson's disease incur Freezing of Gait (FoG), which is not
 addressed adequately by medication. Cueing is a proven strategy to overcome FoG. The Cue2Walk
 is a device with automated detection of FoG and provision of rhythmic cues. In this study,
 the (cost-)effectiveness of the Cue2Walk device as compared to usual care is investigated.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06416345
Device Trial